Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells

Anti-estrogens as hormone therapy are the mainstay treatment for estrogen receptor (ER)-positive breast cancer. ER inhibitors through modulating the transcriptional function of ER have been the frontline anti-estrogens to which refractory phenotype often developed in advanced cancer. The anti-estrog...

Full description

Saved in:
Bibliographic Details
Published in:American journal of cancer research 2021-01, Vol.11 (9), p.4455-4469
Main Authors: Lin, You-Zhe, Lee, Chuan-Chun, Cho, Der-Yang, Wang, Yuan-Liang, Chen, Chia-Yun, Weng, Ching-Yu, Chiu, Shao-Chih, Hung, Mien-Chie, Wang, Shao-Chun
Format: Article
Language:English
Subjects:
Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 4469
container_issue 9
container_start_page 4455
container_title American journal of cancer research
container_volume 11
creator Lin, You-Zhe
Lee, Chuan-Chun
Cho, Der-Yang
Wang, Yuan-Liang
Chen, Chia-Yun
Weng, Ching-Yu
Chiu, Shao-Chih
Hung, Mien-Chie
Wang, Shao-Chun
description Anti-estrogens as hormone therapy are the mainstay treatment for estrogen receptor (ER)-positive breast cancer. ER inhibitors through modulating the transcriptional function of ER have been the frontline anti-estrogens to which refractory phenotype often developed in advanced cancer. The anti-estrogen fulvestrant is currently the only clinically approved pure anti-estrogen which causes ER degradation. However, resistance to fulvestrant still occurs and unfortunately it leaves few choices other than chemotherapy as the later-line treatments to fulvestrant-resistant tumors. Here we show that fulvestrant resistance was accompanied by increased expression of a number of innate immune response genes including the natural killer (NK) cell ligand B7-H6 on the cell surface. In an attempt to overcome the drug resistance phenotype, a NK-based molecular approach taking advantage of a chimeric antigen receptor (CAR) system targeting B7-H6 was established and tested in cells with acquired resistance to fulvestrant. The results demonstrate that the cell therapy approach as a single agent can effectively induce cell death of the resistant cancer cells which is enhanced by the increased expression of cell surface B7-H6. This approach departs from the traditional strategies of conquering anti-estrogen resistant breast cancer and offers a new avenue to eradicate hormone-refractory malignant solid tumors.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8493389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2583310959</sourcerecordid><originalsourceid>FETCH-LOGICAL-p173t-eab79f5c7424dffaee96fec92d809337206a6ed52732514c9251f75d8d6708cd3</originalsourceid><addsrcrecordid>eNpVj9tKAzEQhhdRbKl9h1x6s7C72ZxuhFI8QUHwcL2kyWwb3U3WHBTf3hQr6NzM_HzwMf9JMW9qQksqGD39c8-KZQivVZ62qkUrzosZbikRXPB5MT6lafIQgnEWuR5tPcgQkZJWgUcKhiGgjE2I0kYUHZJoSh5QTqaEEL3bgUWfJu7RevVYRi9t0EmBRlbG5OWA3sww_KouirNeDgGWx70oXm6un9d35ebh9n692pRTzXAsQW6Z6IlibdPqvpcAgvagRKN5JTBmTUUlBU0ahhtStxmQumdEc01ZxZXGi-Lqxzul7Qhagc2PDd3kzSj9V-ek6f4Ta_bdzn10vM1-LrLg8ijw7j3lnt1owqGCtOBS6BrCMa4rQQT-BuZCcyw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2583310959</pqid></control><display><type>article</type><title>Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells</title><source>PubMed Central</source><creator>Lin, You-Zhe ; Lee, Chuan-Chun ; Cho, Der-Yang ; Wang, Yuan-Liang ; Chen, Chia-Yun ; Weng, Ching-Yu ; Chiu, Shao-Chih ; Hung, Mien-Chie ; Wang, Shao-Chun</creator><creatorcontrib>Lin, You-Zhe ; Lee, Chuan-Chun ; Cho, Der-Yang ; Wang, Yuan-Liang ; Chen, Chia-Yun ; Weng, Ching-Yu ; Chiu, Shao-Chih ; Hung, Mien-Chie ; Wang, Shao-Chun</creatorcontrib><description>Anti-estrogens as hormone therapy are the mainstay treatment for estrogen receptor (ER)-positive breast cancer. ER inhibitors through modulating the transcriptional function of ER have been the frontline anti-estrogens to which refractory phenotype often developed in advanced cancer. The anti-estrogen fulvestrant is currently the only clinically approved pure anti-estrogen which causes ER degradation. However, resistance to fulvestrant still occurs and unfortunately it leaves few choices other than chemotherapy as the later-line treatments to fulvestrant-resistant tumors. Here we show that fulvestrant resistance was accompanied by increased expression of a number of innate immune response genes including the natural killer (NK) cell ligand B7-H6 on the cell surface. In an attempt to overcome the drug resistance phenotype, a NK-based molecular approach taking advantage of a chimeric antigen receptor (CAR) system targeting B7-H6 was established and tested in cells with acquired resistance to fulvestrant. The results demonstrate that the cell therapy approach as a single agent can effectively induce cell death of the resistant cancer cells which is enhanced by the increased expression of cell surface B7-H6. This approach departs from the traditional strategies of conquering anti-estrogen resistant breast cancer and offers a new avenue to eradicate hormone-refractory malignant solid tumors.</description><identifier>ISSN: 2156-6976</identifier><identifier>EISSN: 2156-6976</identifier><identifier>PMID: 34659898</identifier><language>eng</language><publisher>e-Century Publishing Corporation</publisher><subject>Original</subject><ispartof>American journal of cancer research, 2021-01, Vol.11 (9), p.4455-4469</ispartof><rights>AJCR Copyright © 2021 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493389/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493389/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,730,783,787,888,53804,53806</link.rule.ids></links><search><creatorcontrib>Lin, You-Zhe</creatorcontrib><creatorcontrib>Lee, Chuan-Chun</creatorcontrib><creatorcontrib>Cho, Der-Yang</creatorcontrib><creatorcontrib>Wang, Yuan-Liang</creatorcontrib><creatorcontrib>Chen, Chia-Yun</creatorcontrib><creatorcontrib>Weng, Ching-Yu</creatorcontrib><creatorcontrib>Chiu, Shao-Chih</creatorcontrib><creatorcontrib>Hung, Mien-Chie</creatorcontrib><creatorcontrib>Wang, Shao-Chun</creatorcontrib><title>Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells</title><title>American journal of cancer research</title><description>Anti-estrogens as hormone therapy are the mainstay treatment for estrogen receptor (ER)-positive breast cancer. ER inhibitors through modulating the transcriptional function of ER have been the frontline anti-estrogens to which refractory phenotype often developed in advanced cancer. The anti-estrogen fulvestrant is currently the only clinically approved pure anti-estrogen which causes ER degradation. However, resistance to fulvestrant still occurs and unfortunately it leaves few choices other than chemotherapy as the later-line treatments to fulvestrant-resistant tumors. Here we show that fulvestrant resistance was accompanied by increased expression of a number of innate immune response genes including the natural killer (NK) cell ligand B7-H6 on the cell surface. In an attempt to overcome the drug resistance phenotype, a NK-based molecular approach taking advantage of a chimeric antigen receptor (CAR) system targeting B7-H6 was established and tested in cells with acquired resistance to fulvestrant. The results demonstrate that the cell therapy approach as a single agent can effectively induce cell death of the resistant cancer cells which is enhanced by the increased expression of cell surface B7-H6. This approach departs from the traditional strategies of conquering anti-estrogen resistant breast cancer and offers a new avenue to eradicate hormone-refractory malignant solid tumors.</description><subject>Original</subject><issn>2156-6976</issn><issn>2156-6976</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVj9tKAzEQhhdRbKl9h1x6s7C72ZxuhFI8QUHwcL2kyWwb3U3WHBTf3hQr6NzM_HzwMf9JMW9qQksqGD39c8-KZQivVZ62qkUrzosZbikRXPB5MT6lafIQgnEWuR5tPcgQkZJWgUcKhiGgjE2I0kYUHZJoSh5QTqaEEL3bgUWfJu7RevVYRi9t0EmBRlbG5OWA3sww_KouirNeDgGWx70oXm6un9d35ebh9n692pRTzXAsQW6Z6IlibdPqvpcAgvagRKN5JTBmTUUlBU0ahhtStxmQumdEc01ZxZXGi-Lqxzul7Qhagc2PDd3kzSj9V-ek6f4Ta_bdzn10vM1-LrLg8ijw7j3lnt1owqGCtOBS6BrCMa4rQQT-BuZCcyw</recordid><startdate>20210101</startdate><enddate>20210101</enddate><creator>Lin, You-Zhe</creator><creator>Lee, Chuan-Chun</creator><creator>Cho, Der-Yang</creator><creator>Wang, Yuan-Liang</creator><creator>Chen, Chia-Yun</creator><creator>Weng, Ching-Yu</creator><creator>Chiu, Shao-Chih</creator><creator>Hung, Mien-Chie</creator><creator>Wang, Shao-Chun</creator><general>e-Century Publishing Corporation</general><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210101</creationdate><title>Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells</title><author>Lin, You-Zhe ; Lee, Chuan-Chun ; Cho, Der-Yang ; Wang, Yuan-Liang ; Chen, Chia-Yun ; Weng, Ching-Yu ; Chiu, Shao-Chih ; Hung, Mien-Chie ; Wang, Shao-Chun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p173t-eab79f5c7424dffaee96fec92d809337206a6ed52732514c9251f75d8d6708cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Lin, You-Zhe</creatorcontrib><creatorcontrib>Lee, Chuan-Chun</creatorcontrib><creatorcontrib>Cho, Der-Yang</creatorcontrib><creatorcontrib>Wang, Yuan-Liang</creatorcontrib><creatorcontrib>Chen, Chia-Yun</creatorcontrib><creatorcontrib>Weng, Ching-Yu</creatorcontrib><creatorcontrib>Chiu, Shao-Chih</creatorcontrib><creatorcontrib>Hung, Mien-Chie</creatorcontrib><creatorcontrib>Wang, Shao-Chun</creatorcontrib><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, You-Zhe</au><au>Lee, Chuan-Chun</au><au>Cho, Der-Yang</au><au>Wang, Yuan-Liang</au><au>Chen, Chia-Yun</au><au>Weng, Ching-Yu</au><au>Chiu, Shao-Chih</au><au>Hung, Mien-Chie</au><au>Wang, Shao-Chun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells</atitle><jtitle>American journal of cancer research</jtitle><date>2021-01-01</date><risdate>2021</risdate><volume>11</volume><issue>9</issue><spage>4455</spage><epage>4469</epage><pages>4455-4469</pages><issn>2156-6976</issn><eissn>2156-6976</eissn><abstract>Anti-estrogens as hormone therapy are the mainstay treatment for estrogen receptor (ER)-positive breast cancer. ER inhibitors through modulating the transcriptional function of ER have been the frontline anti-estrogens to which refractory phenotype often developed in advanced cancer. The anti-estrogen fulvestrant is currently the only clinically approved pure anti-estrogen which causes ER degradation. However, resistance to fulvestrant still occurs and unfortunately it leaves few choices other than chemotherapy as the later-line treatments to fulvestrant-resistant tumors. Here we show that fulvestrant resistance was accompanied by increased expression of a number of innate immune response genes including the natural killer (NK) cell ligand B7-H6 on the cell surface. In an attempt to overcome the drug resistance phenotype, a NK-based molecular approach taking advantage of a chimeric antigen receptor (CAR) system targeting B7-H6 was established and tested in cells with acquired resistance to fulvestrant. The results demonstrate that the cell therapy approach as a single agent can effectively induce cell death of the resistant cancer cells which is enhanced by the increased expression of cell surface B7-H6. This approach departs from the traditional strategies of conquering anti-estrogen resistant breast cancer and offers a new avenue to eradicate hormone-refractory malignant solid tumors.</abstract><pub>e-Century Publishing Corporation</pub><pmid>34659898</pmid><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 2156-6976
ispartof American journal of cancer research, 2021-01, Vol.11 (9), p.4455-4469
issn 2156-6976
2156-6976
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8493389
source PubMed Central
subjects Original
title Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-18T13%3A39%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Suppression%20of%20breast%20cancer%20cells%20resistant%20to%20a%20pure%20anti-estrogen%20with%20CAR-transduced%20natural%20killer%20cells&rft.jtitle=American%20journal%20of%20cancer%20research&rft.au=Lin,%20You-Zhe&rft.date=2021-01-01&rft.volume=11&rft.issue=9&rft.spage=4455&rft.epage=4469&rft.pages=4455-4469&rft.issn=2156-6976&rft.eissn=2156-6976&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2583310959%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p173t-eab79f5c7424dffaee96fec92d809337206a6ed52732514c9251f75d8d6708cd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2583310959&rft_id=info:pmid/34659898&rfr_iscdi=true